 | Up a level |
Peters, Solange; Danson, Sarah; Ejedepang, Dunson; Dafni, Urania; Hasan, Baktiar; Radcliffe, Hoi-Shen; Bustin, Frederique; Crequit, Jacky; Coate, Linda; Guillot, Monica; Surmont, Veerle; Rauch, Daniel; Rudzki, Jakob; O'Mahony, Deirdre; Barneto Aranda, Isidoro; Scherz, Amina; Tsourti, Zoi; Roschitzki-Voser, Heidi; Pochesci, Alessia; Demonty, Gaston; ... (2021). Combined, patient-level, analysis of two randomised trials evaluating the addition of denosumab to standard first-line chemotherapy in advanced NSCLC - The ETOP/EORTC SPLENDOUR and AMGEN-249 trials. Lung cancer, 161, pp. 76-85. Elsevier 10.1016/j.lungcan.2021.09.002
Peters, Solange; Danson, Sarah; Hasan, Baktiar; Dafni, Urania; Reinmuth, Niels; Majem, Margarita; Tournoy, Kurt G; Mark, Michael T; Pless, Miklos; Cobo, Manuel; Rodriguez-Abreu, Delvys; Falchero, Lionel; Moran, Teresa; Ortega Granados, Ana Laura; Monnet, Isabelle; Mohorcic, Katja; Sureda, Bartomeu Massutí; Betticher, Daniel; Demedts, Ingel; Macias, Jose Antionio; ... (2020). A Randomized Open-Label Phase III Trial Evaluating the Addition of Denosumab to Standard First-Line Treatment in Advanced NSCLC: The European Thoracic Oncology Platform (ETOP) and European Organisation for Research and Treatment of Cancer (EORTC) SPLENDOUR Trial. Journal of thoracic oncology, 15(10), pp. 1647-1656. Elsevier 10.1016/j.jtho.2020.06.011
Dziadziuszko, Rafal; Smit, Egbert F; Dafni, Urania; Wolf, Juergen; Wasąg, Bartosz; Biernat, Wojciech; Finn, Stephen P; Kammler, Roswitha; Tsourti, Zoi; Rabaglio, Manuela; Ruepp, Barbara; Roschitzki-Voser, Heidi; Stahel, Rolf A; Felip, Enriqueta; Peters, Solange (2019). Afatinib in NSCLC With HER2 Mutations: Results of the Prospective, Open-Label Phase II NICHE Trial of European Thoracic Oncology Platform (ETOP). Journal of thoracic oncology, 14(6), pp. 1086-1094. Elsevier 10.1016/j.jtho.2019.02.017
